tiprankstipranks
MetaVia (MTVA)
NASDAQ:MTVA
US Market
MTVA
MetaVia
RESEARCH TOOLSreports
Want to see MTVA full AI Analyst Report?

MetaVia (MTVA) Stock News & Sentiment

482 Followers
Fein Reiterates Buy on MetaVia, Keeps DA-1726-Driven Price Target Unchanged at $20
Premium
Ratings
Fein Reiterates Buy on MetaVia, Keeps DA-1726-Driven Price Target Unchanged at $20
3d ago
MTVA
MetaVia Showcases Key Cardiometabolic Data at ADA 2026
Premium
Company Announcements
MetaVia Showcases Key Cardiometabolic Data at ADA 2026
3d ago
8K
MTVA
MetaVia Highlights Strong DA-1726 Phase 1 Weight-Loss Data
Premium
Company Announcements
MetaVia Highlights Strong DA-1726 Phase 1 Weight-Loss Data
6d ago
8K
MTVA
MetaVia to Present New DA-1726 Obesity Data at EASL
Premium
Company Announcements
MetaVia to Present New DA-1726 Obesity Data at EASL
10d ago
8K
MTVA
MetaVia Advances DA-1726 Obesity Trial With First Patient
Premium
Company Announcements
MetaVia Advances DA-1726 Obesity Trial With First Patient
1M ago
8K
MTVA
MetaVia (MTVA): Differentiated Dual-Agonist Obesity Therapy and Solid Cash Runway Underpin Buy Rating
Premium
Ratings
MetaVia (MTVA): Differentiated Dual-Agonist Obesity Therapy and Solid Cash Runway Underpin Buy Rating
2M ago
MTVA
Maintaining Buy on MetaVia: Advancing DA-1726 Clinical Profile and Differentiated Obesity/MASH Strategy Despite Reduced Target Price
Premium
Ratings
Maintaining Buy on MetaVia: Advancing DA-1726 Clinical Profile and Differentiated Obesity/MASH Strategy Despite Reduced Target Price
2M ago
MTVA
More MTVA News >

MTVA News on the Web

Fein Reiterates Buy on MetaVia, Keeps DA-1726-Driven Price Target Unchanged at $20
TipRanks News
Bullish
MetaVia Showcases Key Cardiometabolic Data at ADA 2026
TipRanks News
Bullish
MetaVia Highlights Strong DA-1726 Phase 1 Weight-Loss Data
TipRanks News
Neutral
MetaVia to Present New DA-1726 Obesity Data at EASL
TipRanks News
Neutral
MetaVia Advances DA-1726 Obesity Trial With First Patient
TipRanks News
Neutral
MetaVia says first patient dosed in Part 3 of Phase 1 trial of DA-1726
TipRanks News
Bullish
MetaVia (MTVA): Differentiated Dual-Agonist Obesity Therapy and Solid Cash Runway Underpin Buy Rating
TipRanks News
Bullish
Maintaining Buy on MetaVia: Advancing DA-1726 Clinical Profile and Differentiated Obesity/MASH Strategy Despite Reduced Target Price
TipRanks News
Bullish

News Score - Last 7 Days

Very Positive
MTVA
Sector Average
Media Buzz
This Week3 articles
Weekly Average0.5 articles
News Sentiment
This Week100%
Sector Average76%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is MTVA’s Media Buzz Sentiment?
3 articles about MTVA were published this week. In an average week, 0.5 articles are published.
    What is MTVA’s weekly average amount of articles?
    In an average week, 0.5 articles about MTVA are published.
      What is MTVA’s News Sentiment?
      100% of articles about MTVA were positive this week, compared to its sector average of 76%.
        Healthcare Stocks that are Trending in the News
        GOSSGossamer Bio
        RLAYRelay Therapeutics
        CGENCompugen
        PROKProKidney
        ROIVRoivant Sciences
        Showing the stocks with the most bullish news sentiment over the past week